30836
document
Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer : randomised , non-inferiority , open trial . PURPOSE This single centre , open labelled , randomised non-inferiority trial compared concurrent chemoradiotherapy with carboplatin versus standard concurrent chemoradiotherapy with cisplatin in patients with locoregionally advanced nasopharyngeal cancer ( NPC ) . PATIENTS AND METHODS From August 1999 to December 2004 , 206 patients with locally advanced NPC were randomised with 101 to cisplatin arm and 105 to carboplatin arm . Planned radiotherapy was the same in both groups . All the patients were evaluated for toxicity and survival according to the as-treated principle . RESULTS With a median follow-up of 26.3 months ( range 3-74.6 months ) , 59 % of patients in the cisplatin arm completed the planned concurrent chemoradiation treatment , compared to 73 % in the carboplatin arm . Forty-two percent of cisplatin patients completed the 3 cycles of adjuvant therapy compared to 70 % in the carboplatin group . There were more renal toxicity , leucopenia , and anaemia in the cisplatin group , and more thrombocytopenia in the carboplatin arm . The 3 year disease free survival rates were 63.4 % for the cisplatin group and 60.9 % for the carboplatin group ( p=0.9613 ) ( HR 0.70 , 95 % confidence interval ( CI ) : 0.50-0.98 ) . The 3 year overall survival rates were 77.7 % and 79.2 % for cisplatin and carboplatin groups , respectively ( p=0.9884 ) ( HR 0.83 , 95 % CI : 0.63-1.010 ) . CONCLUSION We concluded that the tolerability of carboplatin based regimen is better than that of the cisplatin regimen . Moreover , the treatment efficacy of carboplatin arm is not different from the standard regimen in the treatment of locoregional advanced stage NPC .
30837
Intervention_Pharmacological
cisplatin
30838
Intervention_Pharmacological
carboplatin
30839
Intervention_Pharmacological
chemoradiotherapy with carboplatin
30840
Intervention_Pharmacological
standard concurrent chemoradiotherapy with cisplatin
30841
Intervention_Pharmacological
cisplatin
30842
Intervention_Pharmacological
carboplatin
30843
Intervention_Pharmacological
Planned radiotherapy
30844
Intervention_Pharmacological
carboplatin
30845
Intervention_Pharmacological
cisplatin
30846
Outcome_Physical
toxicity
30847
Outcome_Mortality
survival
30848
Outcome_Mental
3 cycles of adjuvant therapy
30849
Outcome_Physical
renal toxicity
30850
Outcome_Physical
leucopenia
30851
Outcome_Physical
anaemia
30852
Outcome_Physical
thrombocytopenia
30853
Outcome_Mortality
3 year disease free survival rates
30854
Outcome_Mortality
3 year overall survival rates
30855
Outcome_Other
tolerability of carboplatin based regimen
30856
Participant_Condition
advanced nasopharyngeal cancer
30857
Participant_Condition
locoregionally advanced nasopharyngeal cancer
30858
Participant_Sample-size
206
30859
Participant_Sample-size
101
30860
Participant_Sample-size
105
30861
Participant_Condition
locoregional advanced stage NPC